SCHEMBL23833399

SCHEMBL23833399

COc1ncc(NC(=O)c2cc(-n3ccnc3)ccn2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
APOBEC3G Q9HC16 2/20 0.46
LMNA P02545 1/20 0.45
CD38 P28907 2/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
PIK3C3 Q8NEB9 3/20 0.42
IDH1 O75874 4/20 0.41
NAMPT P43490 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GRM4 Q14833 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151038 1.00 MAPT (0.46) MAPTALDH1A1MEN1KMT2AAPOBEC3G
SCHEMBL30151089 0.76 SMN1; SMN2 (0.47) MAPTALDH1A1MEN1KMT2AAPOBEC3G
SCHEMBL23846407 0.76 MEN1 (0.51) MAPTALDH1A1MEN1KMT2AAPOBEC3G
SCHEMBL23833441 0.76 SMN1; SMN2 (0.47) MAPTALDH1A1MEN1KMT2AAPOBEC3G
SCHEMBL23833405 0.75 MAPT (0.53) MAPTALDH1A1MEN1KMT2AAPOBEC3G
SCHEMBL30151007 0.74 EGFR (0.51) MAPTMEN1KMT2ALMNAIDH1
SCHEMBL23833491 0.74 EGFR (0.51) MAPTMEN1KMT2ALMNAIDH1
SCHEMBL30363908 0.74 CD38 (0.52) KMT2ACD38CYP3A4CYP2D6
SCHEMBL25136084 0.74 CD38 (0.52) KMT2ACD38CYP3A4CYP2D6
SCHEMBL23833492 0.73 KDM4E (0.59) MAPTALDH1A1MEN1KMT2AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MAPT 66/4885ALDH1A1 2592/4885MEN1 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.